Cancer treatment
The personalisation of cancer treatments is leading to better outcomes for patients. It will also pave the way to cures
Jun 11th 2016 | CHICAGO | From the print edition
Timekeeper
“CURE” is not a word much used by oncologists. The best they normally talk of is “remission”. But the past five years have begun to change that. More than 70 new drugs have come to market, and describing the consequences of some of them as revolutionary is not hyperbole—at least for those patients lucky enough to respond positively to them. Being given a diagnosis of advanced melanoma, for example, was once tantamount to being handed a death warrant. Median life expectancy after such news was six to nine months. But recently developed “immuno-oncology” drugs, which co-opt the immune system to fight tumours, are so effective that, in around a fifth of cases, there is talk among experts that the patients involved have actually been cured.
This sort of upbeat news is reinvigorating the study of cancer. At this year’s meeting of the American Society of Clinical Oncology (ASCO), held this week in Chicago, doctors had a spring in their step. Not only do they have new drugs to deploy, they are also developing better ways of using existing ones. They are getting better at diagnosis, too, finding methods to study the weak spots of cancers in parts of the body conventional biopsies cannot reach, and also to pin down tumours that were previously unlocatable. The upshot is that they are beginning to be able to tailor treatments to the needs of individual patients, an approach called personalised medicine. [More...]
On target
The personalisation of cancer treatments is leading to better outcomes for patients. It will also pave the way to cures
Jun 11th 2016 | CHICAGO | From the print edition
Timekeeper
“CURE” is not a word much used by oncologists. The best they normally talk of is “remission”. But the past five years have begun to change that. More than 70 new drugs have come to market, and describing the consequences of some of them as revolutionary is not hyperbole—at least for those patients lucky enough to respond positively to them. Being given a diagnosis of advanced melanoma, for example, was once tantamount to being handed a death warrant. Median life expectancy after such news was six to nine months. But recently developed “immuno-oncology” drugs, which co-opt the immune system to fight tumours, are so effective that, in around a fifth of cases, there is talk among experts that the patients involved have actually been cured.
This sort of upbeat news is reinvigorating the study of cancer. At this year’s meeting of the American Society of Clinical Oncology (ASCO), held this week in Chicago, doctors had a spring in their step. Not only do they have new drugs to deploy, they are also developing better ways of using existing ones. They are getting better at diagnosis, too, finding methods to study the weak spots of cancers in parts of the body conventional biopsies cannot reach, and also to pin down tumours that were previously unlocatable. The upshot is that they are beginning to be able to tailor treatments to the needs of individual patients, an approach called personalised medicine. [More...]
No comments:
Post a Comment